In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Leadership

Set Alert for Leadership

Novo Ventures Remains Bullish After ‘Very Active’ Year

In this latest installment of VC playbook, In Vivo speaks to Naveed Siddiqi, senior partner at Novo Ventures. He discusses the group’s strategy, the European investment outlook for life sciences and how COVID-19 has permanently shifted perceptions of the biopharma industry.

VC Playbook Business Strategies

Snapshot: March Highlights

A selection of articles you might have missed from March 2021, including exclusive interviews with industry leaders and a deeper dive into drug development and R&D.

Business Strategies Companies

Execs On The Move, March 2021

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Appointments BioPharmaceutical

COVID-19 – A Catalyst For Change In Patient Centricity

Astellas’ chief medical officer, Bernie Zeiher, shares perspectives on how COVID-19 has forced the health care industry to think differently about patients’ diverse needs and how the best of these changes must become the norm in delivering patient-focused innovations.

C-Suite Speaks Clinical Trials

Eight Themes That Will Shape Biopharma In Transformational 2021

A year after COVID-19 first turned the world upside down, executives across the biopharma industry consider what 2021 holds in store. The impact of the pandemic will have profound and long-lasting implications for a sector that has been at the heart of responding to the global health challenge.

Business Strategies Commercial

The New Insider Game In Latin America Biotech

Venture capital funds in Latin America have overlooked biotech, leaving an untapped opportunity for local capital markets and US and European investors alike. Chilean entrepreneur Cristian Hernandez, founder of newly launched boutique VC Zentynel Frontier Investments, explains how business – and society – can benefit from launching biotech start-ups able to serve a global market at lower cost.

VC Playbook South America

Centessa ‘Creates Pharma Pipeline Overnight’ Using Novel R&D Approach

With $250m in series A funding, Cambridge, MA-based Centessa is looking to upend traditional biopharma R&D models. The new company was created through the merger of 10 private biotechs, which will sit under the Centessa umbrella as subsidiaries.

Deals Research and Development Strategies

Execs On The Move, February 2021

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Appointments BioPharmaceutical

VC View: Riding The Waves Of Asia’s Healthtech Explosion

Asia continues to gain attention for its healthtech innovation and adoption activity, and VC investors have seen the merits of a maintaining a focus on this newly emerging regional innovation hotspot, regardless of the pandemic.

VC Playbook Medical Device

Carving Out New Spaces In Cancer Immunotherapy

With a combined $335m raised in a crossover series B funding and an IPO last summer, Cambridge, MA-based iTeos Therapeutics has the juice to move its two cancer immunotherapy clinical programs forward.

Financing ImmunoOncology

Direct To Consumer Approach Underscores Femtech’s Disruptive Potential

A new technology accelerator, FemTech Lab, will support the scale-up of at least 10 firms in 2021 that have innovative solutions for issues affecting women’s health and wellbeing. The founders talk to In Vivo about their view of the femtech market and how it will impact traditional health care.

Commercial Companies

Will 2021 Be A Turning Point For Pharnext?

After manufacturing issues disrupted a Phase III study for its lead pipeline candidate, Pharnext believes it is back on track with new management, a fresh clinical trial and strong guidance from regulators. New CEO David Horn Solomon has blockbuster expectations for the company’s rare disease drug. 

Business Strategies C-Suite Speaks
See All
UsernamePublicRestriction

Register